Table 1 Characteristics of 207 patients with TAK
From: Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis
N = 207 | |
|---|---|
Age, years, mean (±SD) | 39.5 ± 13.2 |
Female sex, n (%) | 174 (84.1) |
Hypertension, n (%) | 100 (48.3) |
Use of antihypertensive drugs, n (%) | 100 (48.3) |
Systolic BP, mmHg, mean (±SD) | 129.3 ± 16.1 |
Diastolic BP, mmHg, mean (±SD) | 75.6 ± 12.6 |
Diabetes mellitus, n (%) | 19 (9.2) |
Smoking, n (%) | 18 (8.7) |
Total cholesterol, mg/dl, mean (±SD) | 180.8 ± 41.0 |
Triglycerides, mg/dl, mean (±SD) | 112.6 ± 66.4 |
HDL cholesterol, mg/dl, mean (±SD) | 56.1 ± 17.0 |
LDL cholesterol, mg/dl, mean (±SD) | 102.2 ± 32.7 |
Framingham risk score, %, median (IQR)a | 4.1 (2.5–8.0) |
BMI, kg/m2, mean (±SD) | 22.5 ± 3.1 |
Hemoglobin, g/dl, mean (± SD) | 12.3 ± 1.5 |
Anemia, n (%) | 84 (40.6) |
ESR, mm/h, median (IQR) | 40.0 (20.0–67.0) |
CRP, mg/l, median (IQR) | 4.0 (1.0–22.0) |
Type of vascular involvement, n (%) | |
I | 48 (23.2) |
IIA | 23 (11.1) |
IIB | 36 (17.4) |
III | 8 (3.9) |
IV | 11 (5.3) |
V | 81 (39.1) |
Pulmonary artery involvement, n (%) | 16 (7.7) |
Aortic regurgitation, n (%) | 61 (29.5) |
Use of glucocorticoids, n (%) | |
None-to-low dose | 85 (41.1) |
Medium-to-high dose | 122 (58.9) |
Use of MTX, n (%) | 126 (60.9) |
Use of AZA, n (%) | 38 (18.4) |
Use of aspirin, n (%) | 123 (59.4) |
Use of statins, n (%) | 123 (59.4) |
Cardiovascular events, n (%) | 41 (19.8) |
Coronary arterial events | 23 (11.1) |
Cerebrovascular events | 15 (7.2) |
Congestive heart failure | 3 (1.4) |